Immatics NV
NASDAQ:IMTX

Watchlist Manager
Immatics NV Logo
Immatics NV
NASDAQ:IMTX
Watchlist
Price: 6.91 USD 0.88%
Market Cap: 824.8m USD
Have any thoughts about
Immatics NV?
Write Note

P/E
Price to Earnings

-14.2
Current
-12.8
Median
22.1
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-14.2
=
Market Cap
831.3m USD
/
Net Income
-55.8m EUR
All Countries
Close
Market Cap P/E
DE
Immatics NV
NASDAQ:IMTX
831.3m USD -14.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -180 740.1
US
Abbvie Inc
NYSE:ABBV
311.8B USD 61.5
US
Amgen Inc
NASDAQ:AMGN
140.7B USD 33.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD 921.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD -215.1
US
Epizyme Inc
F:EPE
94.1B EUR -472.7
AU
CSL Ltd
ASX:CSL
134.4B AUD 31.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD 16.8
US
Seagen Inc
F:SGT
39.3B EUR -54.7
NL
argenx SE
XBRU:ARGX
36B EUR -135.6
Earnings Growth P/E to Growth
DE
Immatics NV
NASDAQ:IMTX
Average P/E: 212.9
Negative Multiple: -14.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.5
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.4
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
921.1
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -215.1
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.6 N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-10.3
2-Years Forward
P/E
-5.4
3-Years Forward
P/E
-4.5

See Also

Discover More